Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.
Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...
Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...
This card offers a high rewards rate in rotating categories, a good 0% APR offer and an unusual bonus that could become a windfall. If you don't mind keeping track of bonus categories that change ...
Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...
Bullish option flow detected in Novavax (NVAX) with 9,851 calls trading, 2x expected, and implied vol increasing over 1 point to 83.26%. Jan-26 ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
4d
Hosted on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
4d
Hosted on MSNNovavax (NVAX) Reports Q4 Loss, Tops Revenue EstimatesNovavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago. These figures are adjusted ...
Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results